Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022

Genetics Investing

Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced that the first patient was dosed in the OPTIC phase 1 trial evaluating ADVM-022 for patients with wet age-related macular degeneration (wet AMD). As quoted in the press release: “We are excited to announce the first …

Adverum Biotechnologies (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced that the first patient was dosed in the OPTIC phase 1 trial evaluating ADVM-022 for patients with wet age-related macular degeneration (wet AMD).

As quoted in the press release:

“We are excited to announce the first patient dosed in our OPTIC phase 1 trial assessing a potential single intravitreal administration of ADVM-022 for wet AMD,” said Leone Patterson, chief executive officer of Adverum Biotechnologies. “This milestone is the next step in bringing a new meaningful option to patients, that may provide long-lasting therapy without the need of chronic or frequent anti-VEGF injections.  We look forward to providing an interim update of this phase 1 by the first quarter of 2020.”

“While significant advances have been made in the management of wet AMD with the introduction of anti-VEGF therapies, there remains a need to address the treatment burden and suboptimal outcomes patients face from the need of repeated dosing,” said Dr. David S. Boyer, Partner at Retina-Vitreous Associates Medical Group and Clinical Professor of Ophthalmology at University of Southern California/Keck School of Medicine. “I am encouraged by the early data on ADVM-022, the potential to provide long-term durability with a single administration of an anti-VEGF therapy for patients and the ease of intravitreal delivery of ADVM-022, which utilizes the current standard of care delivery method.  With these combined, ADVM-022 has the potential to be the next paradigm shift in treating wet AMD.”

Click here to read the full press release.

The Conversation (0)
×